ERA Media Release - Mr Rashed Bouresly

The ERA Stewards opened an inquiry on Thursday 29th August 2019, in relation to a stable inspection at the Ras Al Khaimah Stables of licensed ERA Trainer Mr. Rashed Bouresly, where a treatment called Ostarine MK-2866 was confiscated. Evidence was taken from Mr. Bouresly, Dr. Kieran Finn (ERA Regulatory Veterinarian) and Mr. Jahfar Nalakath (Chief Analyst –Equine Forensic Unit). The following matters were established during the inquiry;
1. On Tuesday 25th June 2019, the ERA Stewards visited the Ras Al Khaimah Stables of Mr. Bouresly for a random stable inspection, with the purpose of conducting out-of-competition testing.
2. During the stable inspection Stewards took six (6) blood samples of Mr. Bouresly’s horses for routine out-of-competition testing, inspected the facilities of the stables, assessed the general welfare of the horses, reviewed his ERA Medication Log Book and inspected the medication room.
3. During the inspection of the medication room, a numerous amount of substances were removed due to being out-of-date and several substances were confiscated for further analysis as their therapeutic veterinary use was unknown.
4. The treatments confiscated and sent for further analysis to the Equine Forensic Unit were;
a. Ostarine MK-2866 Oral Solution;
b. Bronchial BD Dialator;
c. MV Chinfield;
d. No Bleeder;
e. Tonicor re;
f. Oxy-Gen;
g. Taipan Injection;
h. Fructosa Vitaminada; and
i. Kinogen Se.
5. On Monday 1st July 2019, the ERA were notified by the Equine Forensic Unit that no prohibited substances were detected in the six (6) blood samples taken for out-of-competition testing on Tuesday 25th June 2019.
6. On Thursday 4th July 2019, the ERA were notified by the Equine Forensic Unit that two (2) of the confiscated treatments returned with substances that could give rise to an offence under ERA Rule 95B, those being;
a) Ostarine MK-2866 Oral Solution; substance detected being Ostarine (Selective Androgen Receptor Modulator – SARMS); and
b) Oxy-Gen; substance detected being Strychnine.
7. Dr. Finn and Mr. Nalakath both stated that Ostarine (SARMS) and Strychnine are both substances analysed for in routine out-of-competition testing under the ERA Rules of Racing, specifically in accordance with ERA Rule 95B 2.
8. Dr. Finn tendered evidence that Ostarine (SARMS) is a selective androgen receptor modulator that works exactly like an anabolic steroid but on selective androgen receptors. Androgen receptors are chemical messages and pathways that when stimulated produce changes consistent with male physical traits such as increase in muscle size and increase in bone density. Anabolic steroids, such as Boldenone and Nandrolone, target all androgen receptors and can have serious unwanted side effects in the body, like liver toxicity and production of oestrogen with female fat deposition. Ostarine has no unwanted side effects and helps with athletic training, giving an unfair advantage.
9. Dr. Finn tendered evidence that Strychnine is an alkaloid found in certain plants. Plants produce strychnine as a deterrent to grazing animals to prevent them from eating that foliage. It is used as a rodenticide. Strychnine causes convulsions by interfering with nerves to muscle pathways, eventually leading to death due to loss of brain function and paralysis of the breathing muscles.
10. On Monday 22nd July 2019, the ERA requested that the Equine Forensic Unit analyse another bottle of Oxy-Gen, which the ERA had possession of, but was not obtained at Mr. Bouresly’s stable.
11. On Thursday 25th July 2019, the ERA were notified by the Equine Forensic Unit that the second bottle of Oxy-Gen analysed returned with the substance Xylazine.
12. Mr. Bouresly tendered evidence that he cannot recall where he obtained the bottle of Oxy-Gen from, and it was only used on one horse. He acknowledged that the product Oxy-Gen was not a reputable substance and that the quality control of the product was questionable. Mr. Bouresly further stated that Ostarine MK-2866 Oral Solution was a sample given to him and he was unaware that it was a banned substance under the ERA Rules. He added that it was never used on any of his horses.
13. The bottle of Ostarine MK-2866 Oral Solution expired on the 15th November 2018.

Due to the lack of information regarding the product Oxy-Gen and that the quality control of the product was questionable, Stewards believed that Mr. Bouresly would not have been aware that Strychnine would have been present in the product, given that it was not listed as one of the ingredients on the bottle. Mr. Bouresly was advised to stop purchasing products form non-reputable companies and to check with the ERA prior to purchasing any new products.

Trainer Mr. Bouresly was found guilty of a charge under the provisions of ERA Rule 95C(i), in that on the 25th June 2019, at his registered training location, Ras Al Khaimah Stables, he had in his possession Ostarine MK-2866 Oral Solution, a selective androgen receptor modulator (SARM), which if administered to a horse at any time could give rise to an offence under ERA Rule 95B.

In considering penalty the Stewards took into account:
• The circumstances of the offence;
• The seriousness of the offence, involving the possession of a substance that has no place in racing;
• General and specific deterrence;
• The integrity and image of racing in the UAE;
• That the Ostarine MK-2866 was an unsolicited sample and he was unaware that it was a breach of the rules to be in possession of the substance; and
• There was no evidence that Ostarine MK-2866 Oral Solution had been administered to any horse in Mr. Bouresly’s care.

Mr. Bouresly was fined the sum of AED 50,000.

Mr. R Bouresly’s record in relation to ERA Rule 95B:
No prior breaches.

Relevant Rules:
ERA Rule 95B 2. (a) (i) erythropoiesis-stimulating agents, including but not limited to erythropoietin (EPO), epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol - epoetin beta (Mircera),
(ii) insulins,
(iii) growth hormones,
(iv) insulin like growth factor-1,
(v) anabolic steroids,
(vi) synthetic proteins and peptides and synthetic analogues of endogenous proteins and peptides not registered for veterinary use,
(vii) selective androgen receptor modulators (SARMS),
(viii) selective estrogen receptor modulators (SERMS),
(ix) selective opiate receptor modulator (SORMS),
(x) other agents that directly or indirectly affect or manipulate gene expression,
(xi) oxygen carriers including but not limited to perfluorochemicals, efaproxiral and modified hemoglobin products,
(xii) venoms of any species or derivatives thereof.
(xiii) Any substance not addressed by any of the proceeding classes of substances, or any substance not universally recognised by veterinary regulatory authorities as valid veterinary therapeutic treatment.

ERA Rule 95C (i) – If in exercising the power under ERA Rule 8A the Stewards identify and/or take possession of any quantity of a substance or preparation that could give rise to an Offence under ERA Rule 95B if administered to a Horse at any time, then any Person in possession of such substance shall be guilty of an Offence and liable to Penalty.

Stewards Panel:
Mr. Sam Shinsky (Chairman), Mr. Taylor Wilson and Mr. Hamad Al Shamsi.